James Elliott

ORCID: 0000-0002-4884-8196
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Veterinary Oncology Research
  • Virus-based gene therapy research
  • Infectious Diseases and Mycology
  • Oral and Maxillofacial Pathology
  • Mast cells and histamine
  • Salivary Gland Tumors Diagnosis and Treatment
  • Cancer Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Animal Genetics and Reproduction
  • Glycosylation and Glycoproteins Research
  • T-cell and B-cell Immunology
  • Head and Neck Surgical Oncology
  • Cancer and Skin Lesions
  • Cancer Diagnosis and Treatment
  • Microbial infections and disease research
  • Tumors and Oncological Cases
  • Theatre and Performance Studies
  • CRISPR and Genetic Engineering
  • Effects of Radiation Exposure
  • Neurofibromatosis and Schwannoma Cases
  • Chemotherapy-related skin toxicity
  • Pediatric Pain Management Techniques
  • Histiocytic Disorders and Treatments
  • Oral health in cancer treatment
  • Veterinary Pharmacology and Anesthesia

North Carolina State University
2019-2020

Willows Veterinary Centre and Referral Service
2014-2019

University of Liverpool
2010-2019

University of Bristol
2017

Royal Victoria Hospital
2003

Queen's University Belfast
2003

Royal Victoria Regional Health Centre
2003

University of Ulster
2003

Prevent Cancer Foundation
1990

Cell and Gene Therapy Catapult
1989

Abstract To determine whether the c‐Ha‐ ras oncogene plays a role in initiation of mammary carcinogenesis, an immortalized human breast epithelial cell line, MCF‐10A, was transfected with plasmid vector pHo6T1 containing T24 Ha‐ and aminoglycoside phosphotransferase gene, which confers resistance to geneticin. Transfected cells exhibited altered pattern growth tridimensional morphology collagen gel. They also anchorage‐independent loss requirement for hormones epidermal factor; addition,...

10.1002/mc.2940040106 article EN Molecular Carcinogenesis 1991-01-01

Abstract Mast cell tumours ( MCTs ) are the most common cutaneous of dogs, however rarely they can arise from oral mucosa. This subset MCT is reported to demonstrate a more aggressive clinical course than those on haired skin and authors hypothesised that dogs with oral, mucosal would have high incidence local lymph node metastasis at presentation this be negative prognostic factor. An additional hypothesis was mitotic index (MI) prognostic. retrospective study examines 33 arising The...

10.1111/vco.12071 article EN Veterinary and Comparative Oncology 2013-11-11

ABSTRACT Early‐delayed side effects (EDSEs) following treatment of canine intracranial meningiomas with 1–3‐fraction stereotactic radiation therapy (SRT) can cause worsening neurologic signs, and one potential method mitigating this toxicity is reducing the dose per fraction. Twenty dogs imaging‐diagnosed telephone follow‐up at least 6 months received a protocol Gy × 5, daily (30 Gy). A ‘possible EDSE’ was defined as mental dullness, exacerbation existing signs or new occurring within 1‐4...

10.1111/vco.13040 article EN Veterinary and Comparative Oncology 2025-01-19

The aim of the study was to report outcome treatment 97 dogs with lymphoma that received a multi-agent chemotherapy protocol containing epirubicin as primary anthracycline. Seventy-five 25-week no maintenance phase whilst 22 phase. Complete response rate 96% and time first relapse (TTR) overall survival (OS) for all were 216 342 days, respectively. Dogs T-cell those classified WHO substage b had significantly poorer OS times TTR. well tolerated toxicity similar doxorubicin-containing...

10.1111/j.1476-5829.2011.00311.x article EN Veterinary and Comparative Oncology 2012-02-28

To assess response and outcome in dogs with stage 4 anal sac apocrine gland adenocarcinoma (ASAGA) treated toceranib phosphate as the sole chemotherapeutic agent.Retrospective case series.15 client-owned ASAGA between March 2013 June 2017.Medical records were reviewed, data collected included signalment, clinical signs, results of physical examinations diagnostic procedures, treatments, response, follow-up information, outcomes. Adverse events to treatment assessed according standard...

10.2460/javma.254.8.960 article EN Journal of the American Veterinary Medical Association 2019-04-02

The aim of the study was to evaluate if thymidine kinase (TK) correlated with duration first remission (DFR) or survival in dogs lymphoma and initial TK levels stage substage; also assess level at diagnosis immunophenotype. assayed 73 treatment naïve lymphoma, then again after treatment; 47% had an above reference interval. Dogs B‐cell higher activities than T‐cell lymphoma. were not disease activity prior associated DFR survival. Where elevated diagnosis, it fell into range during...

10.1111/j.1476-5829.2011.00296.x article EN Veterinary and Comparative Oncology 2011-12-08

A ten‐year‐old, female‐entire English springer spaniel presented with a large intra‐abdominal mass but no other clinical signs. Gastrointestinal stromal tumour of the caecum widespread abdominal metastasis was confirmed. Treatment toceranib phosphate resulted in complete response, despite absence exon‐8 or exon‐11 c‐kit mutation. There evidence recurrence nine months after diagnosis.

10.1111/jsap.12657 article EN Journal of Small Animal Practice 2017-02-15

Objectives To assess the prevalence of gastrointestinal toxicity in dogs receiving chemotherapy with vincristine and cyclophosphamide efficacy maropitant citrate ( Cerenia™ , Zoetis) reducing these events. Methods Dogs or were randomised to either receive not period immediately after treatment for 4 days afterwards. Owners completed a diary adverse events following treatment. Results Adverse occurred 40/58 (69%) group. Most mild included: lethargy (62%), appetite loss (43%), diarrhoea (34%)...

10.1111/jsap.12237 article EN Journal of Small Animal Practice 2014-06-11

Anal sac adenocarcinoma is uncommon in cats. We report the outcome of multi-modality therapy two cats (surgery, definitive radiotherapy and systemic chemotherapy) surgery alone All received surgical excision primary tumour followed by carboplatin chemotherapy cases. Both that underwent multimodal developed distant metastatic disease one recurrence tumour. One cat with incomplete margins also rapid recurrence. Overall survival times were 89, 161 169 days. had complete still alive without 425...

10.1016/j.jfms.2011.06.005 article EN Journal of Feline Medicine and Surgery 2011-07-27

Multi‐agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first‐line to treatment‐naïve canine lymphoma patients with measurable, high grade T‐cell (HGTCL). All responded CEOP LEOP. Toxicity typical of multi‐agent protocols 25% dogs receiving exhibited mild‐to‐moderate ALT elevation 29% 3 4 neutropenia. Median progression‐free survival (100 versus 269 days) overall (155 327 were significantly higher in LEOP...

10.1111/avj.12847 article EN Australian Veterinary Journal 2019-07-22

Epitheliotropism is an important diagnostic feature of cutaneous epitheliotropic lymphoma and canine histiocytoma; however, although noted in certain feline mastocytic diseases, it has not been considered a mast cell tumor. In this study, 3 tumors had invasion neoplastic cells into the epidermis follicular epithelium. This unusual histologic finding was characterized by infiltrates individual clusters stratum basale spinosum. The origin these documented demonstration metachromasia with...

10.1177/0300985812451626 article EN Veterinary Pathology 2012-06-13

Nineteen cats with relapsed high-grade/large-cell lymphoma were treated dexamethasone, melphalan, actinomycin-D and cytarabine (DMAC). All had received Cyclophosphamide, Vincristine, Prednisolone (COP) as first-line chemotherapy most at least 2 prior rescue agents 14 of 19 having both epirubicin lomustine. Five (26%) exhibited a response (defined an improvement or resolution tumour-associated clinical signs/tumour volume, complete/partial response) to though no patients more than cycles...

10.1111/vco.12360 article EN Veterinary and Comparative Oncology 2017-10-16

Temozolomide ( TMZ ) is an alkylating agent previously used in conjunction with doxorubicin DOX to treat dogs relapsed lymphoma. However, there are very limited data for this drug when as single agent. The aim of retrospective study was evaluate the efficacy and toxicity multicentric lymphoma that failed multi‐agent chemotherapy protocols, compare outcome a group receiving same combination . Twenty‐six patients were included 11 / group. Responses evaluated via review medical records. overall...

10.1111/vco.12335 article EN Veterinary and Comparative Oncology 2017-08-02

To summarise the clinical presentation and outcomes in a series of miniature schnauzers diagnosed with histiocytic sarcoma.Retrospective review medical records sarcoma between 2008 2019 at two referral centres UK. Signalment, signs initial presentation, imaging results clinico- histopathological findings, treatment type outcome were recorded. Progression-free survival overall time calculated.Thirty dogs included. Twenty-four 29 undergoing thorax had lung and/or mediastinal involvement. The...

10.1111/jsap.13139 article EN cc-by Journal of Small Animal Practice 2020-04-22

Paraneoplastic syndromes (PNSs) can be described as the indirect effects of tumours, typically due to tumour production and release biologically active substances such hormones, growth factors cytokines. PNSs are sometimes first evidence a neoplastic disease; therefore, knowledge these their associated types help in early diagnosis. should resolve with treatment underlying and, conversely, may return recurrence tumour. In some cases, they cause more significant morbidity than itself, so must...

10.1136/inp.g5826 article EN In Practice 2014-10-01

Background The Flat‐coated Retriever (FCR) is a breed at‐risk for histiocytic sarcoma (HS). A haemophagocytic form of HS (HPHS) occurs in the spleen ± other sites such as bone marrow, and CD11d+ disease macrophage origin. Patients with HPHS typically present regenerative anaemia. Lomustine well‐accepted, first‐line chemotherapy dogs HS, but its specific utility has not been previously reported. Methods cohort 10 presumptively diagnosed via splenic marrow or liver aspiration cytology were...

10.1111/avj.12767 article EN Australian Veterinary Journal 2018-11-26

The DMAC protocol (dexamethasone, melphalan, actinomycin-D, cytarabine) has been evaluated in American studies for the treatment of relapsed canine lymphoma, comparing similarly to other rescue protocols. aim this study was evaluate efficacy and toxicity DMAC, a larger UK cohort resistant lymphomas. Medical records dogs with non-Hodgkin high-grade lymphomas that received as were reviewed from 2007 2017. Response, time initiation discontinuation (TTD) (Veterinary Cooperative Oncology Group...

10.1111/vco.12457 article EN Veterinary and Comparative Oncology 2019-01-23

Abstract/Summary Bacterial vaginosis is a common condition among women of reproductive age and associated with potentially serious side-effects, including an increased risk preterm birth. Recent advancements in microbiome sequencing technologies have produced novel insights into the complicated mechanisms underlying bacterial given rise to new methods diagnosis. Here we report on validation quantitative, molecular diagnostic algorithm based relative abundances ten pathogenic bacteria four...

10.1101/334177 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2018-05-30

Abstract Thirty dogs with macroscopic plasma cell tumours (PCTs) were treated radiation therapy (RT). Twelve patients palliative‐intent prescriptions (range, 4‐10 Gy/fraction (median, 7 Gy/fraction) for a total dose of 20 to 35 Gy (median 30 Gy). Eighteen received definitive‐intent 3.0‐4.2 3 42 54 48 Involved sites included the oral cavity, skin, multiple myeloma (MM)‐associated lytic bone lesions, (solitary osseous plasmacytoma; SOP), nasal larynx, retrobulbar space, lymph node and rectum....

10.1111/vco.12600 article EN Veterinary and Comparative Oncology 2020-04-19
Coming Soon ...